

**LEUCOVORIN CALCIUM- leucovorin calcium tablet**  
**Teva Pharmaceuticals USA, Inc.**

-----  
**Leucovorin Calcium Tablets USP**

0484

0485


**Rx only**

**DESCRIPTION**

Leucovorin calcium tablets USP contain either 5 mg or 25 mg leucovorin as the calcium salt of *N*-[4-[[[(2-amino-5-formyl-1, 4, 5, 6, 7, 8-hexahydro-4-oxo-6-pteridiny]methyl] amino]benzoyl]-*L*-glutamic acid. This is equivalent to 5.4 mg or 27.01 mg of anhydrous leucovorin calcium, respectively. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The 25 mg tablet also contains D&C yellow no. 10 aluminum lake and FD&C blue no. 1 aluminum lake.

Leucovorin is a water soluble form of reduced folate in the folate group; it is useful as an antidote to drugs which act as folic acid antagonists. These tablets are intended for oral administration only.

The structural formula is as follows:



$C_{20}H_{21}CaN_7O_7$  M.W. 511.5

**CLINICAL PHARMACOLOGY**

Leucovorin is a racemic mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The biologically active compound of the mixture is the (-)-*L*-isomer, known as *Citrovorum factor*, or (-)-folinic acid. Leucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “one-carbon” moieties. Following oral administration, leucovorin is rapidly absorbed and enters the general body pool of reduced folates. The increase in plasma and serum folate activity (determined microbiologically with *Lactobacillus casei*) seen after oral administration of leucovorin is predominantly due to 5-methyltetrahydrofolate.

Twenty normal men were given a single, oral 15 mg dose (7.5 mg/m<sup>2</sup>) of leucovorin calcium and serum folate concentrations were assayed with *L. casei*. Mean values observed ( $\pm$  one standard error) were:

- a. Time to peak serum folate concentration:  $1.72 \pm 0.08$  hours,
- b. Peak serum folate concentration achieved:  $268 \pm 18$  ng/mL,
- c. Serum folate half-disappearance time: 3.5 hours.

Oral tablets yielded areas under the serum folate concentration-time curves (AUCs) that were 12% greater than equal amounts of leucovorin given intramuscularly and equal to the same amounts given intravenously.

Oral absorption of leucovorin is saturable at doses above 25 mg. The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg and 37% for 100 mg.

## **INDICATIONS AND USAGE**

Leucovorin calcium tablets are indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdoses of folic acid antagonists.

## **CONTRAINDICATIONS**

Leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin B<sub>12</sub>. A hematologic remission may occur while neurologic manifestations continue to progress.

## **WARNINGS**

In the treatment of accidental overdosage of folic acid antagonists, leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin's effectiveness in counteracting hematologic toxicity decreases.

Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.

Delayed methotrexate excretion may be caused by a third space fluid accumulation (i.e., ascites, pleural effusion), renal insufficiency, or inadequate hydration. Under such circumstances, higher doses of leucovorin or prolonged administration may be indicated. Doses higher than those recommended for oral use must be given intravenously.

Leucovorin may enhance the toxicity of fluorouracil. Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.<sup>1</sup> Concomitant granulocytopenia and fever were present in some but not all of the patients.

The concomitant use of leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of *Pneumocystis carinii* pneumonia in patients with HIV infection was associated with increased rates of treatment failure and mortality in a placebo-controlled study.

## **PRECAUTIONS**

### **General**

Parenteral administration is preferable to oral dosing if there is a possibility that the patient may vomit or not absorb the leucovorin. Leucovorin has no effect on other established toxicities of methotrexate such as the nephrotoxicity resulting from drug and/or metabolite precipitation in the kidney.

### **Drug Interactions**

Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and

primidone, and increase the frequency of seizures in susceptible children.

Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than usual methotrexate concentrations following intrathecal administration. However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.

Leucovorin may enhance the toxicity of fluorouracil (see **WARNINGS**).

## **Pregnancy**

### ***Teratogenic Effects***

#### ***Pregnancy Category C***

Animal reproduction studies have not been conducted with leucovorin. It is also not known whether leucovorin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Leucovorin should be given to a pregnant woman only if clearly needed.

## **Nursing Mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when leucovorin is administered to a nursing mother.

## **Pediatric Use**

See Drug Interactions subsection.

## **ADVERSE REACTIONS**

Allergic sensitization, including anaphylactoid reactions and urticaria, has been reported following the administration of both oral and parenteral leucovorin.

## **OVERDOSAGE**

Excessive amounts of leucovorin may nullify the chemotherapeutic effect of folic acid antagonists.

## **DOSAGE AND ADMINISTRATION**

Leucovorin calcium tablets are intended for oral administration. Because absorption is saturable, oral administration of doses greater than 25 mg is not recommended.

### **Impaired Methotrexate Elimination or Inadvertent Overdosage**

Leucovorin rescue should begin as soon as possible after an inadvertent overdosage and within 24 hours of methotrexate administration when there is delayed excretion (see **WARNINGS**). Leucovorin 15 mg (10 mg/m<sup>2</sup>) should be administered IM, IV, or PO every 6 hours until serum methotrexate level is less than 10<sup>-8</sup> M. In the presence of gastrointestinal toxicity, nausea, or vomiting, leucovorin should be administered parenterally.

Serum creatinine and methotrexate levels should be determined at 24 hour intervals. If the 24 hour serum creatinine has increased 50% over baseline or if the 24 hour methotrexate level is greater than 5 x 10<sup>-6</sup> M or the 48 hour level is greater than 9 x 10<sup>-7</sup> M, the dose of leucovorin should be increased to 150 mg (100 mg/m<sup>2</sup>) IV every 3 hours until the methotrexate level is less than 10<sup>-8</sup> M. Doses greater than 25 mg should be given parenterally (see **CLINICAL PHARMACOLOGY**).

Hydration (3 L/d) and urinary alkalinization with sodium bicarbonate should be employed concomitantly. The bicarbonate dose should be adjusted to maintain the urine pH at 7 or greater.

The recommended dose of leucovorin to counteract hematologic toxicity from folic acid antagonists with less affinity for mammalian dihydrofolate reductase than methotrexate (i.e., trimethoprim, pyrimethamine) is substantially less, and 5 to 15 mg of leucovorin per day has been recommended by some investigators.

Patients who experience delayed early methotrexate elimination are likely to develop reversible non-oliguric renal failure. In addition to appropriate leucovorin therapy, these patients require continuing hydration and urinary alkalization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen to below 0.05 micromolar and the renal failure has resolved.

Some patients will have abnormalities in methotrexate elimination or renal function following methotrexate administration, which are significant but less severe. These abnormalities may or may not be associated with significant clinical toxicity. If significant clinical toxicity is observed, leucovorin rescue should be extended for an additional 24 hours (total 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate elimination or binding to serum albumin) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed.

## HOW SUPPLIED

Leucovorin Calcium Tablets USP, 5 mg are available as white, round, unscored, biconvex tablets, debossed with **b** on one side and **484** on the other side, packaged in bottles of 30 (NDC 0555-0484-01), 100 (NDC 0555-0484-02) and 1000 (NDC 0555-0484-05) tablets.

Leucovorin Calcium Tablets USP, 25 mg are available as pale green, round, unscored, biconvex tablets, debossed with **b** on one side and **485** on the other side, packaged in bottles of 25 (NDC 0555-0485-27) and 500 (NDC 0555-0485-04) tablets.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

**Protect from light and moisture.**

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

## REFERENCES

1. Grem JL, Shoemaker DD, Petrelli NJ, Douglas HO. Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma. *Cancer Treat Rep* 1987;71:1122.
2. Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J Med* 1986;314:1600-1606.

**TEVA PHARMACEUTICALS USA, INC.**

North Wales, PA 19454

Rev. A 5/2016

**Package/Label Display Panel**

NDC 0555-0484-01

**Leucovorin  
Calcium  
Tablets USP**  
**5 mg\***


**Rx only**

**30 TABLETS**

**TEVA**

\* Each tablet contains  
leucovorin calcium, USP  
equivalent to 5 mg leucovorin.  
**Usual Dosage:** See package insert  
for full prescribing information.  
Store at 20° to 25°C (68° to 77°F)  
[See USP Controlled Room  
Temperature].  
Protect from light and moisture.  
Dispense in a tight, light-resistant  
container as defined in the USP,  
with a child-resistant closure  
(as required).  
**KEEP THIS AND ALL  
MEDICATIONS OUT OF THE  
REACH OF CHILDREN.**  
TEVA PHARMACEUTICALS USA, INC.  
North Wales, PA 19454  
799-32-100744 Rev. A 5/2016

**Non Varnish Area  
For Lot/Exp**



Leucovorin Calcium Tablets USP 5 mg 30s Label Text

NDC 0555-0484-01

Leucovorin

Calcium

Tablets USP

5 mg\*

Rx only

30 TABLETS

TEVA

Package/Label Display Panel

NDC 0555-0485-27

**Leucovorin  
Calcium  
Tablets USP**  
**25 mg\***

**Rx only**

**25 TABLETS**

**TEVA**

\* Each tablet contains leucovorin calcium, USP equivalent to 25 mg leucovorin.  
**Usual Dosage:** See package insert for full prescribing information.  
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].  
Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).  
**KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.**  
**TEVA PHARMACEUTICALS USA, INC.**  
North Wales, PA 19454  
NDC 0555-0485-27  
799-32-100748 Rev. A 5/2016

**Non Varnish Area  
For Lot/Exp**

**Leucovorin Calcium Tablets USP 25 mg 25s Label Text**

NDC 0555-0485-27

**Leucovorin**

**Calcium**

**Tablets USP**

**25 mg\***

**Rx only**

**25 TABLETS**

**TEVA**

**LEUCOVORIN CALCIUM**

leucovorin calcium tablet

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:0555-0484
<b>Route of Administration</b>	ORAL		

**Active Ingredient/Active Moiety**

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
LEUCOVORIN CALCIUM (UNII: RPR1R4C0P4) (LEUCOVORIN - UNII:Q573I9DVLP)	LEUCOVORIN	5 mg

**Inactive Ingredients**

<b>Ingredient Name</b>	<b>Strength</b>
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)	

LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)				
MAGNESIUM STEARATE (UNII: 70097M6I30)				
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)				
Product Characteristics				
Color	WHITE	Score	no score	
Shape	ROUND	Size	8mm	
Flavor		Imprint Code	b;484	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0555-0484-01	30 in 1 BOTTLE; Type 0: Not a Combination Product	06/30/1990	
2	NDC:0555-0484-02	100 in 1 BOTTLE; Type 0: Not a Combination Product	06/30/1990	
3	NDC:0555-0484-05	1000 in 1 BOTTLE; Type 0: Not a Combination Product	06/30/1990	
Marketing Information				
Marketing Category	Application Number or Monograph Citation		Marketing Start Date	Marketing End Date
ANDA	ANDA071198		06/30/1990	

LEUCOVORIN CALCIUM			
leucovorin calcium tablet			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0555-0485
Route of Administration	ORAL		
Active Ingredient/Active Moiety			
Ingredient Name		Basis of Strength	Strength
LEUCOVORIN CALCIUM (UNII: RPR1R4C0P4) (LEUCOVORIN - UNII:Q573I9DVLP)		LEUCOVORIN	25 mg
Inactive Ingredients			
Ingredient Name			Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)			
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)			
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)			
MAGNESIUM STEARATE (UNII: 70097M6I30)			
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)			
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)			
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)			

### Product Characteristics

<b>Color</b>	GREEN (pale green)	<b>Score</b>	no score
<b>Shape</b>	ROUND	<b>Size</b>	8mm
<b>Flavor</b>		<b>Imprint Code</b>	b;485
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0555-0485-04	500 in 1 BOTTLE; Type 0: Not a Combination Product	06/30/1990	
2	NDC:0555-0485-27	25 in 1 BOTTLE; Type 0: Not a Combination Product	06/30/1990	

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA071199	06/30/1990	

**Labeler** - Teva Pharmaceuticals USA, Inc. (001627975)

Revised: 5/2016

Teva Pharmaceuticals USA, Inc.